Know Cancer

or
forgot password

Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention


N/A
9 Years
13 Years
Open (Enrolling)
Female
Cervical Cancer

Thank you

Trial Information

Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention


Inclusion Criteria:



- Age 9-13 at first HPV vaccine dose

- Mother/legal guardian and daughter are both interested and willing to have the girl
receive the HPV vaccine

- Mother/legal guardian and daughter both indicate that they would be able to return to
clinic for the three vaccine doses

Exclusion Criteria:

- Girls with a known history of any allergies or severe reaction to any vaccines, food
or medicine

- Pregnant adolescents will be excluded. If a girl becomes pregnant after the first
dose is administered, she will not be provided with the second or third dose

- Girls with moderate or severe illnesses will be asked to postpone vaccination eg.
Pneumonia.

- Girls with a weakened immune system, cancer, leukemia, AIDS or other immune system
problems

- Girls with a bleeding disorder or currently taking anticoagulants

- Girls that have received any other vaccinations in the past 4 weeks

- Girls currently on steroids, such as cortisone, prednisone, or anti-cancer drug.

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Outcome Measure:

Determine the population coverage of HPV vaccination of girls aged 9-13 offered within the context of cervical cancer screening and treatment of mothers

Outcome Description:

The aim of the study to assess whether we can fully vaccinate (all 3 doses),50% of girls aged 9 -13 in the participating districts, in an 18-month period. This corresponds to 4000 girls in Thailand and 4000 in Phillipines. The study will seek to undertand if this level of population coverage (50%), can be achieved through encouraging women that recive cervical cancer screening to bring in their daughters or relatives for vaccination.

Outcome Time Frame:

18 months

Safety Issue:

No

Principal Investigator

Cecilia Llave, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Cancer Institute Foundation, Phillipines

Authority:

United States: Johns Hopkins School of Public Helath Institutional Review Board

Study ID:

36448

NCT ID:

NCT01096134

Start Date:

January 2011

Completion Date:

June 2012

Related Keywords:

  • Cervical Cancer
  • Uterine Cervical Neoplasms

Name

Location